Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Moody's Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Moody's Corporation trades at $479.75 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 2.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Moody's Corporation pays a 0.86% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MCO | |
|---|---|---|
Market Cap | $29.60B | $82.52B |
Sector | Health | Financials |
52-Week High | $491.22 | $539.61 |
52-Week Low | $205.48 | $412.23 |
Enterprise Value | $27.56B | $88.54B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
MCO trades at $477.84, showing minimal daily movement (-0.06%) amid a bearish technical signal. The company demonstrates strong fundamentals with 15% revenue growth in Q2 2026 and consistent earnings beats, achieving a 34.25% net income margin. Recent news highlights institutional repositioning into credit rating companies, with MCO benefiting from robust debt issuance and AI-related analytics demand.
Outlook remains positive with a $561.88 consensus price target (17.6% upside), though valuation multiples appear elevated. Key risks include competitive pressures and market sensitivity to credit cycles. The combination of strong profitability, analyst support (56% buy ratings), and strategic positioning in credit analytics supports a constructive view despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
